Luisanna M. Sánchez

Luisanna M. Sánchez

Auto-generated profile, based on publicly available information

Luisanna M. Sánchez

Department of Pediatrics, Robert Reid Cabral Hospital Infantil, Santo Domingo, Dominican Republic

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Blood Advances
Verified
Journal Article
Open access
RNRosa M. Nieves
Rosa M. Nieves
TLTeresa Latham
Teresa Latham
NMNicolle Marte
Nicolle Marte
MBMelissa Berges
Melissa Berges
LSLuisanna M. Sánchez
Luisanna M. Sánchez
RWRussell E. Ware Ware
Russell E. Ware Ware
Sickle cell anemia (SCA) is recognized globally, but little is known about affected Hispanic populations. In partnership with the Dominican Republic, a Hispanic Caribbean island with a large SCA population, a transcranial Doppler (TCD) screening program provided hydroxyurea to children with conditional velocities. Building local capacity, 10 Dominican medical graduates were certified in TCD examinations and trained in hydroxyurea management. The Stroke Avoidance for Children in REpública Dominicana (SACRED) trial enrolled 283 children with average age of 8.7 ± 3.4 years and 130 (46%) females. At initial screening, treatment-naïve children with conditional velocities (170-199 cm/s) were younger (6.6 ± 2.7 vs 8.9 ± 3.4 years; P = .0002) and more anemic (hemoglobin, 7.4 ± 0.8 vs 8.0 ± 1.2 g/dL; P = .0046) than children with normal screening velocities (<170 cm/s). Among 57 treatment-naïve children receiving 6 months of fixed-dose hydroxyurea at 20 mg/kg per day, average TCD velocities decreased by 20 cm/s, and 61% became normal. Compared with fixed-dose hydroxyurea, dose escalation to maximum tolerated dose (MTD) led to fewer sickle-related events with incidence rate ratio 0.59, 95% confidence intervals 0.36 to 0.98, P = .0420. At MTD, TCD benefits were sustained over 5 years, with 81% reverting to normal and an average TCD velocity decrease of 27 cm/s. Brain magnetic resonance imaging documented substantial baseline parenchymal disease; during treatment, 10% developed new vasculopathy, plus 1 stroke and 1 death. The SACRED trial documents a high burden of cerebrovascular disease among Hispanic children with SCA and demonstrates the feasibility of partnership to establish TCD screening programs, the utility of hydroxyurea to reduce TCD velocities and reduce stroke risk, and sustained benefits of hydroxyurea dose escalation. This trial was registered at www.clinicaltrials.gov as #NCT02769845.

14 January 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
JRJenny Ruiz
Jenny Ruiz
JRJoanna M. Robles
Joanna M. Robles
LSLuisanna M. Sánchez
Luisanna M. Sánchez
AKAlisa Khan
Alisa Khan
ALAmy D. Lu
Amy D. Lu
PAPaula Aristizabal
Paula Aristizabal
Language‐discordant healthcare encounters—when the patient/caregiver and clinician are not able to communicate directly in the patient's/caregiver's preferred language—are associated with worse quality of care, increased adverse events, and research exclusion. Here, we describe the current state of language justice in clinical practice and research in the United States, Canada, and Spain, discuss the role of social determinants of health and language in patient safety and health outcomes, and review an example of culturally and linguistically concordant interventions to increase research participation. We close with practical and global strategies to increase multilingual research participation and to provide equitable patient‐ and family‐centered care in pediatric hematology‐oncology.

2 June 2017 in JMIR Research Protocols
Verified
Journal Article
Open access
NJNeelum D Jeste
Neelum D Jeste
LSLuisanna M Sánchez
Luisanna M Sánchez
GUGabriela S Urcuyo
Gabriela S Urcuyo
MBMelissa E Bergés
Melissa E Bergés
JLJudy P Luden
Judy P Luden
RWRussell E. Ware Ware
Russell E. Ware Ware
In the Dominican Republic, where the burden of sickle cell anemia (SCA) is high, many children lack access to routine screening and preventative care. Children with SCA are at risk for stroke, an event that leads to significant morbidity and mortality. In the United States, screening via transcranial Doppler (TCD) identifies children with SCA at highest stroke risk, allowing early intervention with blood transfusions. The need for indefinite transfusions for primary stroke prevention limits their practicality in limited-resource countries. Hydroxyurea has been shown to lower TCD velocities and to prevent conversion from conditional (170 to 199 cm/sec) to abnormal (greater than or equal to 200 cm/sec) velocities. In resource-limited settings, implementation of a TCD screening program, coupled with hydroxyurea therapy, could reduce the burden of SCA and stroke. The aims of the Stroke Avoidance for Children in REpública Dominicana (SACRED) trial are (1) to screen children with SCA for stroke risk using TCD and to determine the prevalence of elevated velocities in a cross-sectional sample; (2) to identify clinical and laboratory correlates of elevated velocities; and (3) to obtain longitudinal data on the natural history of TCD velocities and to measure therapeutic effects of hydroxyurea. This prospective trial, designed and conducted by Cincinnati Children's Hospital Medical Center (CCHMC) and Hospital Infantil Robert Reid Cabral (HIRRC) with Centro de Obstetricia y Ginecología, includes a baseline cross-sectional epidemiological survey of the distribution of TCD velocities across a large cohort of children with SCA in the Dominican Republic. Children with conditional velocities are eligible to begin protocol-directed hydroxyurea if laboratory criteria are met. The treatment schedule begins with a fixed-dose of approximately 20 mg/kg/day for 6 months, after which it escalates to maximum tolerated dose (MTD). All participants undergo longitudinal annual TCD evaluation, while those on hydroxyurea have semi-annual evaluations during the 3-year study period. Data are collected using an Internet-based Research Electronic Data Capture (REDCap) system with forms translated into Spanish; both remote and on-site monitoring are used. To date, 122 children with SCA have enrolled in SACRED including 85 (69.7%, 85/122) with normal, 29 (23.8%, 29/122) with conditional, 5 (4.1%, 5/122) with abnormal, and 3 (2.5%, 3/122) with inadequate TCD velocities. Of the 29 children with conditional TCD velocities, 17 (59%, 17/29) have initiated hydroxyurea per protocol, with plans for escalation to MTD. The SACRED trial will provide novel epidemiologic data about the prevalence of children with SCA and increased stroke risk in the Dominican Republic. The study also includes an investigation of the impact of hydroxyurea at MTD on elevated TCD velocities, as well as clinical and laboratory parameters. The design and implementation of SACRED reflect a successful international institutional partnership, one that features local capacity building and training in research methods and clinical care. The trial's results have important implications for screening and prevention of primary stroke in children with SCA living in resource-limited settings. ClinicalTrials.gov NCT02769845; https://www.clinicaltrials.gov/ct2/show/NCT02769845 (Archived by WebCite at http://www.webcitation.org/6qf6n0Egh).

25 July 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
JSJosaura Fernandez Sanchez
Josaura Fernandez Sanchez
LSLuisanna M. Sánchez
Luisanna M. Sánchez
SKSarah S. Kappa
Sarah S. Kappa
CKCecile L. Karsenty
Cecile L. Karsenty
MOMadeleine O'KEefe
Madeleine O'KEefe
JPJacquelyn M. Powers
Jacquelyn M. Powers

26 August 2026 in Blood Red Cells & Iron
Verified
Journal Article
Open access
LSLuisanna M. Sánchez
Luisanna M. Sánchez
AJAmanda Jacobson-Kelly
Amanda Jacobson-Kelly

30 September 2026 in Journal of Adolescent Health
Verified
Journal Article
Open access
IJIsaac A. Janson
Isaac A. Janson
AOAmanda I. Okolo
Amanda I. Okolo
JMJoshua I. Miller
Joshua I. Miller
KHKathy L. Hassell
Kathy L. Hassell
HTHeather Taylor
Heather Taylor
LSLuisanna M. Sánchez
Luisanna M. Sánchez